<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806464</url>
  </required_header>
  <id_info>
    <org_study_id>VG161-C102</org_study_id>
    <nct_id>NCT04806464</nct_id>
  </id_info>
  <brief_title>Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer</brief_title>
  <official_title>A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects With Advanced Primary Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CNBG-Virogin Biotech (Shanghai) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CNBG-Virogin Biotech (Shanghai) Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study&#xD;
      will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are&#xD;
      refractory to conventional therapies. This is an open label study and it's divided into two&#xD;
      parts.&#xD;
&#xD;
      Part 1: This part is ascending dose design to determine the safety and tolerability of VG161&#xD;
      and find recommended dose of VG161.&#xD;
&#xD;
      Part 2: This part is extended dose design to determine the effectiveness of VG161.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: This part will be conducted in 5 dose ascending cohorts, including 1 single dose&#xD;
      accelerated titration design pilots and 4 multiple dose escalation groups. Descriptive&#xD;
      statistics will be used to summarize data.&#xD;
&#xD;
      Part 2: This part will only include the part 1 recommended dose. Hypothesis test and&#xD;
      descriptive statistics will be used to summarize data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part1: MTD/Recommended dose</measure>
    <time_frame>7 month</time_frame>
    <description>MTD (Maximum tolerable dose) /Recommended dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part1: Occurence of DLT</measure>
    <time_frame>1month</time_frame>
    <description>Occurence of DLT (Dose Limiting Toxicity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part1: Numbers of DLT</measure>
    <time_frame>1 month</time_frame>
    <description>Numbers of DLT (Dose Limiting Toxicity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part1: Occurence of AE and SAE（NCI CTCAE 5.0）</measure>
    <time_frame>7 months</time_frame>
    <description>Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part1: Frequency of AE and SAE（NCI CTCAE 5.0）</measure>
    <time_frame>7 months</time_frame>
    <description>Frequency of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part2:ORR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Objective Response Rate by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part1:Tmax(h)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part1:Cmax(copies/ugDNA)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part1:ORR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Objective Response Rate by iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part1:DOR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Disease Control Rate by iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part1:PFS</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate medium Progression Free Survival by iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part1:OS rate</measure>
    <time_frame>17 months</time_frame>
    <description>Evaluate Overall Survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:CD3+, CD4+, CD8+</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of CD3+, CD4+, CD8+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:IL15</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of IL15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:PD-L1, PD-1</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of PD-L1, PD-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:PFS</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate medium Progression Free Survival by iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:OS rate</measure>
    <time_frame>17 months</time_frame>
    <description>Evaluate Overall Survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: OS</measure>
    <time_frame>17 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:DOR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Disease Control Rate by iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Safety indicators：AEs</measure>
    <time_frame>7 months</time_frame>
    <description>Incidence of adverse events (NCI CTCAE 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Safety indicators：ECOG</measure>
    <time_frame>7 months</time_frame>
    <description>Incidence of abnormal ECOG scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Safety indicators：12-lead electrocardiograms</measure>
    <time_frame>7 months</time_frame>
    <description>Incidence of abnormal 12-lead electrocardiograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Safety indicators：laboratory tests results</measure>
    <time_frame>7 months</time_frame>
    <description>Incidence of abnormal laboratory tests results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:CD3+, CD4+, CD8+</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of CD3+, CD4+, CD8+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:IL15</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of IL15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:PD-L1, PD-1</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of PD-L1, PD-1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part1:&#xD;
1.0*10^8 PFU on Day 1&#xD;
1.0*10^8 PFU on Days 1 to 2&#xD;
1.0*10^8 PFU on Days 1 to 3&#xD;
1.0*10^8 PFU on Days 1 to 4&#xD;
1.0*10^8 PFU on Days 1 to 5&#xD;
Part2:&#xD;
Depends on the recommended dose in Part1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))</intervention_name>
    <description>Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>VG161</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. According to 'The Diagnostic and Therapeutic Criteria for Primary Liver Cancer' (NMPA,&#xD;
             2019 Edition), subject with advanced primary hepatocellular carcinoma, intrahepatic&#xD;
             cholangiocarcinoma, combined hepatocellular which is refractory/relapsed after and/or&#xD;
             intolerant of standard therapies or for which no standard therapy exists.&#xD;
&#xD;
          2. There are tumor lesions intrahepatic and / or extrahepatic metastases that can be&#xD;
             injected under B ultrasound and meet the volume requirements of the current dose&#xD;
             group, and the longest diameter of injectable tumor lesion &gt;1.5cm（or the shortest&#xD;
             diameter of lymph node lesions）&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) scores 0 or 1.&#xD;
&#xD;
          4. Life expectancy is at least 3 months.&#xD;
&#xD;
          5. Required organ function:&#xD;
&#xD;
        1) Hematology blood (no blood transfusion or colony stimulating factor treatment within 14&#xD;
        days): absolute neutrophil count (ANC)≥1.5×10^9L, platelets (PLT)≥75×10^9L, hemoglobin&#xD;
        (Hb)≥85g/L, lymphocyte (LYM)≥0.8×10^9L; 2) Liver function: Total Serum bilirubin&#xD;
        (TBIL)≤1.5×ULN (the upper limit of the reference range), Alanine aminotransferase&#xD;
        (ALT)≤5×ULN, aspartate aminotransferase (AST)≤5×ULN; 3)Child-Pugh A-B level; 4) Renal&#xD;
        function: Serum creatinine≤1.5×ULN, and creatinine clearance≥45 ml/min (calculated per&#xD;
        Cockcroft-Gault formula); 5) Coagulation function: activated partial thromboplastin time&#xD;
        (APTT)≤1.5×ULN, prothrombin time(PT) ≤1.5×ULN, international standardized ratio&#xD;
        (INR)≤1.5×ULN.&#xD;
&#xD;
        6.If HBsAg is positive or HBcAb is positive ,must meet HBV-DNA&lt;10^3 IU/ml. Subject with&#xD;
        positive HBsAg must follow 'Guidelines for the prevention and treatment of chronic&#xD;
        hepatitis B' (2019 Edition) for antiviral treatment.&#xD;
&#xD;
        7.Subjects of childbearing potential (male and female) must agree to use a reliable&#xD;
        contraceptive method (hormone or barrier method or abstinence) during the study and for at&#xD;
        least 90 days following the last dose; females of childbearing potential must have a&#xD;
        negative blood pregnancy test within 7 days of study enrollment.&#xD;
&#xD;
        8.Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy,&#xD;
             endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment&#xD;
             initiation.&#xD;
&#xD;
          2. Transcatheter arterial chemoembolization(TACE) within 4 weeks of study treatment&#xD;
             initiation&#xD;
&#xD;
          3. Participation in clinical trials of any other investigational agents within 4 weeks of&#xD;
             study treatment initiation.&#xD;
&#xD;
          4. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks&#xD;
             of study treatment initiation.&#xD;
&#xD;
          5. Patients who received systemic treatment with either corticosteroids ( &gt;10 mg/ daily&#xD;
             prednisone or equivalent) or other immunosuppressive medications within 14 days of&#xD;
             study treatment initiation.&#xD;
&#xD;
          6. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior&#xD;
             anti-cancer therapy (except for toxicity that the investigator assessed to be no&#xD;
             safety risk, such as alopecia.).&#xD;
&#xD;
          7. Subjects with Central Nervous System (CNS) metastasis or meningeal metastasis .&#xD;
&#xD;
          8. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM).&#xD;
&#xD;
          9. Subjects with the relapse of HSV infection and relevant clinical manifestations, such&#xD;
             as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes.&#xD;
&#xD;
         10. Subjects with other uncontrolled active infections.&#xD;
&#xD;
         11. Known history of immunodeficiency and test positive of human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
         12. History of severe cardiovascular disease:&#xD;
&#xD;
        1)Ventricular arrhythmias requiring clinical intervention; 2)QTc interval &gt;480 ms; 3)Acute&#xD;
        coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III&#xD;
        grade or above within 6 months; 4)The cardiac function grade≥II or left ventricular&#xD;
        ejection fraction (LVEF) &lt;50% per the New York Heart Association (NYA); 5)Uncontrolled&#xD;
        hypertension.&#xD;
&#xD;
        13. Subjects with active or past autoimmune diseases that are likely to recur (e.g.&#xD;
        systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for&#xD;
        patients with clinically stable autoimmune thyroiditis.&#xD;
&#xD;
        14. known to have alcohol or drug dependence. 15. Persons with mental disorders or poor&#xD;
        compliance. 16. Pregnant or lactating women. 17. Subjects with any significant unrelated&#xD;
        systemic illness that to the investigator's opinion would compromise the subject's&#xD;
        eligibility to participate the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingbo Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingbo Liang, MD.PhD.</last_name>
    <phone>0571-87236666</phone>
    <email>liangtingbo@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yinan Shen, MD. PhD.</last_name>
      <email>fysyn@163.com</email>
    </contact>
    <investigator>
      <last_name>Tingbo Liang, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

